Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.
Clicks: 194
ID: 112552
1996
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
194 views
25 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #80 of 105 articles by views in Antimicrobial agents and chemotherapy
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment ...
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (35 words).
Try re-searching for a better abstract.
| Reference Key |
crawford1996antimicrobialphase
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | D M Lewinsohn, R A Bowden, D Mattson, S W Crawford;D M Lewinsohn;R A Bowden;D Mattson;S W Crawford; |
| Journal | Antimicrobial agents and chemotherapy |
| Year | 1996 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.